Former Vice President of Sales to focus on key value driversContinue reading
Author Archive: AZBio
Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
- uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis aid pathologists in providing faster, more accurate patient diagnoses in breast cancer
- In combination with the VENTANA DP 200 slide scanner and Roche uPath enterprise software, the new algorithms provide innovative digital pathology solutions to advance personalised healthcare
- Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year.1 About 15 to 20 percent of women diagnosed with breast cancer are HER2 positive.2
State, Partners Opening 24/7 COVID-19 Vaccination Site At State Farm Stadium
Operation Expands Availability With More Arizonans Prioritized For VaccineContinue reading
Economic Impact Payments on their way, visit IRS.gov instead of calling
Looking for your second round of Economic Impact Payment? Learn about eligibility, the process, and how to track your payment.Continue reading
I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic
I Peace’s GMP-grade iPSCs are key to manufacture Avery Therapeutics’ MyCardia™, a proprietary tissue-engineered heart graft developed to treat heart failureContinue reading
Connect2STEM 2021 Returns as Dynamic Virtual Experience on Saturday January 30
Live Kickoff Event Celebrates 10 Years of Arizona’s Statewide SciTech Festival Continue reading
Moderna Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.
- Total of 200 million doses ordered by the U.S government to date; U.S. government retains option to purchase up to an additional 300 million doses
- Approximately 20 million doses will be delivered by the end of December 2020
- Moderna intends to submit a Biologics License Application for full U.S. licensure in 2021
Payroll R&D Credit Five Years Later: Forging a New Path
By John Guy, Manager, Emerging Companies Policy at Biotechnology Innovation Organization
HTG Announces First Collaborator in Early Access Program for its Prototype Whole Transcriptome Panel
TUCSON, Ariz., Dec. 18, 2020 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has signed up the first collaborator in its recently announced Early Access Program for its prototype whole transcriptome panel.Continue reading
Ivy Brain Tumor Center Initiates Phase 0 Clinical Trial with BeiGene for Newly Diagnosed and Recurrent Glioblastoma
Trial Represents First-Ever Phase 0 for Newly Diagnosed Patients with Glioblastoma. The Ivy Brain Tumor Center’s Phase 0 clinical trials program is the largest of its kind in the world and enables personalized care in a fraction of the time and cost associated with traditional drug development.Continue reading